Davis Polk advised Coloplast on its acquisition of Nine Continents Medical, an early stage company pioneering an implantable tibial nerve stimulation treatment for over-active bladder. The acquisition price consists of $145 million upfront cash payment and an additional contingent future milestone payment.
Danish medical device company Coloplast develops products and services designed to make life easier for people with intimate health conditions. Coloplast listens to end-users to better understand their needs and responds by bringing the best ideas to market in the form of medical devices and service solutions.Founded in 2014, Nine Continents Medical is a privately held company that has developed an innovative solution for over-active bladder.
The Davis Polk corporate team included partner Harold Birnbaum and associate Jae Maeng. Partner David R. Bauer and associate Hilary Smith provided intellectual property advice. Partner Veronica M. Wissel and associate Abigail Lane provided executive compensation advice. Partner William A. Curran and associate Danielle Rapaccioli provided tax advice. Partner John B. Reynolds III provided regulatory advice. Partner Jesse Solomon provided antitrust advice. Members of the Davis Polk team are based in the New York and Washington DC offices.